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Abstract 
Real-time visualizations of drug 
pharmacokinetics and pharmacodynamics may help 
anesthesiologists more accurately titrate intravenous 
anesthetics for sedation and analgesia in a critical 
care setting. To assess synergism between propofol 
and opioids, our laboratory has developed response 
surface pharmacodynamic interaction models for 
remifentanil and propofol. These models use 
surrogate measures of analgesia and sedation from a 
volunteer study but must be validated before they are 
applied to patients in a real-time display; the 
surrogate measures used in the volunteer study must 
be related to clinical patient responses. The aim of 
this study is to explore the pharmacodynamic 
relationship between the surrogate and clinical 
responses. We hypothesize that the surrogate stimuli 
from the volunteer study can be mapped to surgical 
stimuli; we expect the levels of anesthesia required to 
moderate responses to the surrogate measures relate 
to levels of sedation and analgesia needed to prevent 
responses to surgical stimuli in the operating room. 
Introduction 
During the development of an anesthetic, 
considerable resources are used to create 
pharmacokinetic profiles. Simply put, 
pharmacokinetics describe what the body does to the 
drug; pharmacokinetic models give the concentration 
ofthe drug in the body as a function of time. Once 
the drug is administered, it is transported in the blood 
to different body tissues, in particular the biophase or 
effect site. The biophase consists of the specific 
tissues, membranes, receptors, and enzymes where 
the drug exerts its pharmacologic effect; the central 
nervous system is the biophase for anesthetics. The 
concentration of anesthetics at the effect site can be 
predicted using pharmacokinetic models. 1 
Our lab developed a computer simulation 
that visualizes the pharmacokinetics of rernifentanil 
and propofol, two, commonly used, intravenous 
anesthetics. (See Figure 1.) Anesthesiologist study 
subjects were asked to maintain a target therapeutic 
drug concentration and stable hemodynamics in a 
simulated patient by directing drug administrations. 
Subjects who were shown the display more closely 
maintained the target concentration and had shorter 
periods of inadequate anesthesia than subjects who 
only used traditional anesthesia monitors. The results 
suggest that the visualization of pharmacokinetic 
models may assist in clinical decision-making. 2 
However, anesthesiologists typically are worried less 
about the drug concentrations than they are about the 
drug effects on their patients. 
Figure 1. Screen shot of computer visualization of 
anesthesia pharmacokinetics, 20 minutes in the past to 10 
minutes in the future. The colored vertical bars represent 
drug boluses. 
Pharmacodynamic models can be defmed as 
what the drug does to the body; pharmacodynamics 
describe the drug effects as functions of the drug 
concentrations at the effect site. Pharmacodynamic 
models are typically sigmoidal in shape for 
anesthetics. (See Figure 2.) The midpoint of the 
curve is called the EC50 value, and is the effect-site 
concentration at which there is a 50% probability that 
the patient is adequately anesthetized. I 
Anesthesiologists generally target the EC95 value 
such that there is a 95% probability that their patients 
will not respond to stimuli. Together, 
pharmacokinetic and pharmacodynamic models 
describe the rate of onset of a drug and the expected 
duration of drug effect. However, anesthesia is 
generally provided using several drugs in 
combination. 
When more than one anesthetic is used, 
there are several possible drug interactions. (See 
Figure 3.) The axes concentrations of Drug A and 
Drug B and the lines indicate an equal level of 
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Figure 2. Sigmoidal shape of a typical pharmacodynamic 
function for a single drug. 
anesthetic effect, called an isobole. When the isobole 
bows towards the origin, the drugs are synergistic, 
such that the drugs given in combination reduces the 
total amount of drug needed to provide a target effect 
level. A straight line suggests that the drugs are 
additive, meaning that there is no interaction between 
them. Ifthe isobole bows away from the origin, then 
the relation is infraadditive or antagonistic, such that 
the higher the concentration of one drug, the greater 
the concentration of the other drug to maintain the 
effect level. When a full range of drug effect, instead 















Figure 3. Isoboles represent pharmacodynamic interactions 
that exert the same drug effect for two drugs in combination . 
Our lab has created response surfaces for 
propofol and remifentanil that describe the drug 
effect for clinical propofol and remifentanil effect-
site concentrations in a non-surgical volunteer study. 
At several propofol-remifentanil concentration pairs, 
noxious stimuli, surrogates for surgical stimuli, were 
applied to the volunteers. The surrogate measures 
were assessment of the subject's alertness (using the 
OAA/S scale), laryngoscopy, electrical tetany, and 
pressure algometry. The response surfaces for these 
four surrogates showed significant synergism 
between remifentanil and propofol.3,4 The surfaces 
for sedation and for laryngoscopy are shown in 
Figure 4. Other studies have shown fentanyl 
cogeners to have related pharmacodynamic effects 
that might be related to one another using a scaling 
factor. 5 Because remifentanil is a fentanyl derivative, 
it is believed that the response surface for propofol 
and remifentanil may actually model propofol-opioid 
pharmacodynamic interactions by using different 
scaling factors for each opioid. 
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Figure 4. Response surfaces for suppressing a response to 
surrogate stimuli (the sedation or OAAlS surface is above, 
the surface for laryngoscopy below). Note that much higher 
levels of drug are needed to provide sufficient analgesia for 
laryngoscopy compared to simply sedating a patient. Also 
note the synergism between propofol and remifentanil. 
Methods 
Data Collection 
With institutional review board approval 
from the University Hospital and informed consent, 
we studied 16 patients (6 males and 10 females) ages 
25 to 64 scheduled for abdominallaparoscopic 
surgery under total intravenous anesthesia. 13 
patients received midazolam (1.5 mg) as a sedative 
before entering the operating room (OR). The 
infusion rates of propofol and of remifentanil were 
digitally acquired. Drug boluses were recorded by 
hand. Patient hemodynamics (non-invasive blood 
pressure and heart rate) and bispectral index (BJS) 
were also acquired digitally. 
The times at loss of consciousness (LaC) 
and recovery of consciousness (ROC) were recorded. 
The adequacy or inadequacy of the anesthetic 
(indicated by movement or a 20% increase in 
baseline heart rate) was observed at selected 
milestones of the surgery (i.e. laryngoscopy and 
intubation, skin incision, trocar placement, intra-
abdominal manipulation, wound closure, and skin 
closure). To ensure that a rise in heart rate was 
indicative of a new painful stimulus, the "baseline 
heart rate" was the average heart rate over the past 
10-15 minutes. 
At the end of surgery, the patient was 
followed into the post-anesthetic care unit (PACU). 
The patient's alertness was scored using the 
observer's assessment of awareness and sedation 
(OANS) once every 5 minutes for a total time ono 
minutes. (A subject in a deep sleep receives a score 
of 1 and a score of 5 indicates that the subject is 
alert.) During this time the patient rated the 
perceived pain (resulting from the surgery) on a scale 
of 0-10 (0 being absolutely no pain, 10 being the 
greatest pain ever experienced). The drug doses were 
also recorded. 
Pharmacokinetic Validation 
Before validating the pharmacodynamic 
models, we validated that the effect-site drug 
concentrations predicted by our program are accurate. 
Predictions from our computer program were 
compared to those of ST ANPUMP, another research 
pharmacokinetic simulator. (ST ANPUMP is freely 
available from the author, Steven L. Shafer, MD, 
Anesthesiology Service (II2A), PA VAMC, 3801 
Miranda Ave., Palo Alto, CA 94304.) We used the 
Marsh model, based on the Gepts model, for 
propofol, the Minto, Schnider model for remifentanil, 
and the Shafer, Varvel, Aziz, and Scott model for 
fentany1.6,7,8 Because the pharmacodynamic response 
surfaces are functions of propofol and remifentanil 
(an opioid), only the simulation scenarios shown in 
Table 1 were compared. 
Table 1: Pharmacokinetic Simulation Scenarios 












100 J.lg /kg/min 
250 J.lg 
.20 J.lg /kg/min 
200 J.lg 
To validate the pharmacodynamic models, 
responses (and non-responses) of patients to surgical 
stimuli were compared to the model predictions. To 
visualize relationships between responses to surgical 
stimuli versus surrogate measures, the predicted 
anesthetic concentrations at the surgical stimuli were 
plotted on the pharmacodynamic response surfaces 
from the volunteer study. 
Comparison between the pharmacokinetic 
simulations showed that our implementations of the 
kinetic models match published models. The results 
of the pharmacokinetic simulations for boluses are 
shown in Figure 5. The infusion simulations showed 
even fewer differences. The model parameters were 
loaded externally into STANPUMP, as the internal 
models were modifications of published models. It is 
also significant to note the challenge of modeling 
rapidly changing drug concentrations, such as occur 
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Figure 4. Comparisons between pharmacokinetic model 
implementations (our simulations and those of STAN PUMP) 
for propofol (the two highest curves), fentanyl (the middle 
curves that are visually indistinguishable), and remifentanil 
(the lowest curves, also indistinguishable). 
Figure 5 contains top-down or topographical 
views of the propofol-remifentanil pharmacodynamic 
response surfaces with EC50 and EC95 isoboles. 
Data points are the predicted concentration pairs of 
propofol and remifentanil at selected clinical events. 
X's represent responses while O's represent no 
response on the laryngoscopy and electrical tetany 
surfaces. Diamonds on the sedation surface represent 
patient recovery of consciousness. For laryngoscopy, 
2 of 5 responses and 5 of 7 non-responses were 
accurately predicted by the model EC95 isobole. For 
skin incision, we observed no responses and 19 of 31 
non-responses were accurately predicted by the 
model EC95 isobole. For recovery of consciousness, 
6 of 11 wake-ups followed the model EC95 
prediction EC95. 
Discussion 
The preliminary data set indicates that the electrical 
tetany and OAAJS response surfaces correlate to skin 
incision and recovery of consciousness, respectively. 
The lack of intraoperative responses presents a 
challenge for validating the response surfaces. It is 
hoped that data from the PACU will include patient 
responses to pain as the anesthetic effect-site 
concentrations decrease. Complete validation and the 
necessary adaptation ofthe PD models will require a 
larger sample size. To extend the models' clinical 
relevance, PD interactions between more anesthetics 
(IV and volatile) are needed. 
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